Sangamo Biosciences (SGMO) Announces ZFN-Mediated Genome Editing Program for Hemoglobinopathie Will Transfer to Bioverativ (BIIB)
Tweet Send to a Friend
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that its collaborative zinc finger nuclease (ZFN)-mediated genome editing program for hemoglobinopathies will transfer ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
